A recent example of co-pending cases involves Viiv Healthcare's abacavir combination drugs — where Apotex's case started 4 months after Teva's case [5]. (slaw.ca)
The Federal Joint Committee (G - BA) specified two appropriate comparator therapies according to the approval status: Treatment - naive patients, i.e. patients who had not been treated for HIV before, were to receive efavirenz in combination with tenofovir and emtricitabine or in combination with abacavir and lamivudine. (sciencedaily.com)
Clinical trials have now shown that screening patients for HLA - B * 5701 before treatment has dramatically reduced the number of side effects being experienced from abacavir use. (yourgenome.org)